Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. AKRO
AKRO logo

AKRO Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
1.62B
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
3.76B
EV/OCF(TTM)
--
P/S(TTM)
--
Akero Therapeutics, Inc. is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Efruxifermin (EFX), its lead product candidate for MASH, is being evaluated in three ongoing Phase 3 studies: SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, and SYNCHRONY Real-World in patients with MASH (F1-F4). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body.
Show More

Events Timeline

(ET)
2025-11-07
07:07:39
Akero Therapeutics Reveals New Results from SYMMETRY and HARMONY Trials
select
2025-10-09 (ET)
2025-10-09
12:00:41
Akero Therapeutics Sees 16.6% Increase
select

News

Globenewswire
7.0
2025-11-20Globenewswire
Halper Sadeh LLC Urges Shareholders of SEE, AXTA, SEMR, and AKRO to Reach Out for Rights Consultation
  • Investigation of Companies: Halper Sadeh LLC is investigating Sealed Air Corporation, Axalta Coating Systems, Semrush Holdings, and Akero Therapeutics for potential violations of federal securities laws and breaches of fiduciary duties related to their sales to other companies.

  • Shareholder Rights: Shareholders of the mentioned companies are encouraged to learn about their rights and options regarding the proposed transactions, with Halper Sadeh LLC offering legal assistance on a contingent fee basis.

  • Legal Support Offered: The law firm represents investors globally who have experienced securities fraud and corporate misconduct, aiming to seek increased consideration and additional disclosures for shareholders.

  • Contact Information: Interested shareholders can contact Halper Sadeh LLC for a free consultation regarding their legal rights, with provided contact details for attorneys Daniel Sadeh and Zachary Halper.

PRnewswire
7.0
2025-11-18PRnewswire
Halper Sadeh LLC Encourages WOW, AKRO, HFWA, BRY Shareholders to Contact the Firm to Discuss Their Rights
  • Investigation of Companies: Halper Sadeh LLC is investigating potential violations of federal securities laws and breaches of fiduciary duties related to the sales and mergers of several companies, including WideOpenWest, Akero Therapeutics, Heritage Financial, and Berry Corporation.

  • Shareholder Rights: Shareholders of the mentioned companies are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options, as the firm may seek increased consideration or additional disclosures on their behalf.

  • Contingent Fee Basis: The firm operates on a contingent fee basis, meaning shareholders will not incur out-of-pocket legal fees unless the case is successful.

  • Legal Support for Investors: Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, aiming to recover losses and implement corporate reforms.

PRnewswire
7.0
2025-11-12PRnewswire
Halper Sadeh LLC Encourages NIC, AKRO, BRNS Shareholders to Contact the Firm to Discuss Their Rights
  • Investigation of Companies: Halper Sadeh LLC is investigating Nicolet Bankshares, Akero Therapeutics, and Barinthus Biotherapeutics for potential violations of federal securities laws and breaches of fiduciary duties to shareholders related to their respective mergers and sales.

  • Shareholder Rights: Shareholders of the mentioned companies are encouraged to contact Halper Sadeh LLC to learn about their rights and options, as the firm may seek increased consideration or additional disclosures on their behalf.

  • Contingent Fee Basis: The legal actions will be handled on a contingent fee basis, meaning shareholders will not incur out-of-pocket expenses for legal fees or costs.

  • Legal Support for Investors: Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, aiming to implement corporate reforms and recover funds for affected investors.

Globenewswire
7.0
2025-11-07Globenewswire
Halper Sadeh LLC Urges Shareholders of JAMF, CADE, AKRO, and GES to Reach Out for Rights Consultation
  • Investigation of Companies: Halper Sadeh LLC is investigating Jamf Holding Corp., Cadence Bank, Akero Therapeutics, and Guess?, Inc. for potential violations of federal securities laws and breaches of fiduciary duties related to their proposed sales.

  • Details of Transactions: The proposed sales include Jamf's sale for $13.05 per share, Cadence's exchange for 2.475 shares of Huntington stock per share, Akero's cash offer of $54.00 per share plus a contingent value right, and Guess?'s sale for $16.75 per share in cash.

  • Shareholder Rights: Shareholders of the mentioned companies are encouraged to learn about their rights and options regarding the transactions, with Halper Sadeh LLC offering legal assistance on a contingent fee basis.

  • Legal Representation: Halper Sadeh LLC represents investors globally, focusing on securities fraud and corporate misconduct, and has a history of recovering funds for defrauded investors.

Globenewswire
8.5
2025-11-06Globenewswire
BRODSKY & SMITH INVESTOR ALERT: Announcing Investigations into Qorvo, Inc. (Nasdaq – QRVO), First Foundation Inc. (NYSE – FFWM), Akero Therapeutics, Inc. (Nasdaq - AKRO), and CoreCard Corporation (NYSE - CCRD)
  • Qorvo Acquisition Investigation: Qorvo, Inc. is set to be acquired by Skyworks for $32.50 in cash and 0.960 shares of Skyworks per Qorvo share, with investigations into whether the Qorvo Board breached fiduciary duties by not ensuring a fair process and deal value for shareholders.

  • First Foundation Merger Inquiry: First Foundation Inc. will merge with FirstSun Capital Bancorp in an all-stock deal, raising concerns about the First Foundation Board's fiduciary duties and the fairness of the deal for its shareholders.

  • Akero Therapeutics Acquisition Scrutiny: Akero Therapeutics, Inc. is being acquired by Novo Nordisk for $54.00 per share plus a contingent value right, with investigations focusing on the Board's adherence to fiduciary duties and the fairness of the transaction for shareholders.

  • CoreCard Corporation Merger Investigation: CoreCard Corporation will merge with Euronet in a stock-for-stock transaction valued at approximately $248 million, prompting inquiries into whether the CoreCard Board fulfilled its fiduciary responsibilities and ensured fair value for shareholders.

PRnewswire
7.0
2025-11-05PRnewswire
Halper Sadeh LLC Encourages AKRO, CADE, FSUN Shareholders to Contact the Firm to Discuss Their Rights
  • Investigation of Companies: Halper Sadeh LLC is investigating Akero Therapeutics, Cadence Bank, and FirstSun Capital Bancorp for potential violations of federal securities laws and breaches of fiduciary duties to shareholders related to their proposed transactions.

  • Details of Transactions: Akero shareholders are set to receive $54.00 per share plus a contingent value right, Cadence shareholders will receive shares of Huntington Bancshares, and FirstSun shareholders will own 59.5% of the merged entity with First Foundation Inc.

  • Legal Support for Shareholders: The law firm offers free consultations to shareholders regarding their rights and options, and may seek increased compensation or additional disclosures on their behalf.

  • Contingent Fee Basis: Halper Sadeh LLC operates on a contingent fee basis, meaning shareholders will not incur out-of-pocket legal fees unless the case is successful.

Wall Street analysts forecast AKRO stock price to rise
10 Analyst Rating
Wall Street analysts forecast AKRO stock price to rise
3 Buy
7 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
54.00
Averages
60.22
High
84.00
Current: 0.000
sliders
Low
54.00
Averages
60.22
High
84.00
H.C. Wainwright
Andrew Fein
initiated
$72
AI Analysis
2025-09-04
Reason
H.C. Wainwright
Andrew Fein
Price Target
$72
AI Analysis
2025-09-04
initiated
Reason
H.C. Wainwright analyst Andrew Fein assumed coverage of Akero Therapeutics with a Buy rating and $72 price target. Th firm says efruxifermin's cirrhosis reversal and Phase 3 readouts support a bullish share view.
TD Cowen
NULL -> Buy
initiated
$76
2025-08-04
Reason
TD Cowen
Price Target
$76
2025-08-04
initiated
NULL -> Buy
Reason
TD Cowen initiated coverage of Akero Therapeutics with a Buy rating and $76 price target. The firm believes the company's efruxifermin, an FGF21 analog, has a "differentiated" clinical profile and see commercial success in metabolic dysfunction-associated steatohepatitis. Efruxifermin, is in Phase 3 trials with high probabilities of success, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for AKRO
Unlock Now

Valuation Metrics

The current forward P/E ratio for Akero Therapeutics Inc (AKRO.O) is -11.92, compared to its 5-year average forward P/E of -8.90. For a more detailed relative valuation and DCF analysis to assess Akero Therapeutics Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-8.90
Current PE
-11.92
Overvalued PE
-4.86
Undervalued PE
-12.93

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-6.20
Current EV/EBITDA
-8.60
Overvalued EV/EBITDA
-2.36
Undervalued EV/EBITDA
-10.03

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

AI Analysis
Annual
Quarterly

Whales Holding AKRO

V
Vivo Capital, LLC
Holding
AKRO
+13.93%
3M Return
S
Summit Partners Public Asset Management, LLC
Holding
AKRO
+13.06%
3M Return
B
Braidwell LP
Holding
AKRO
+9.48%
3M Return
P
Perceptive Advisors LLC
Holding
AKRO
+9.34%
3M Return
F
Frazier Life Sciences Management, LP
Holding
AKRO
+6.90%
3M Return
A
Avoro Capital Advisors LLC
Holding
AKRO
+5.97%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Akero Therapeutics Inc (AKRO) stock price today?

The current price of AKRO is 0 USD — it has increased 0

What is Akero Therapeutics Inc (AKRO)'s business?

Akero Therapeutics, Inc. is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Efruxifermin (EFX), its lead product candidate for MASH, is being evaluated in three ongoing Phase 3 studies: SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, and SYNCHRONY Real-World in patients with MASH (F1-F4). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body.

What is the price predicton of AKRO Stock?

Wall Street analysts forecast AKRO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AKRO is60.22 USD with a low forecast of 54.00 USD and a high forecast of 84.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Akero Therapeutics Inc (AKRO)'s revenue for the last quarter?

Akero Therapeutics Inc revenue for the last quarter amounts to -90.24M USD, increased 10.44

What is Akero Therapeutics Inc (AKRO)'s earnings per share (EPS) for the last quarter?

Akero Therapeutics Inc. EPS for the last quarter amounts to -67171000.00 USD, decreased -4.62

How many employees does Akero Therapeutics Inc (AKRO). have?

Akero Therapeutics Inc (AKRO) has 63 emplpoyees as of April 02 2026.

What is Akero Therapeutics Inc (AKRO) market cap?

Today AKRO has the market capitalization of 1.62B USD.